Welcome to our dedicated page for Bausch + Lomb Corporation SEC filings (Ticker: BLCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bausch + Lomb Corporation (BLCO) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, drawn directly from the EDGAR system. As a Canadian-incorporated issuer with common shares listed on the New York Stock Exchange and the Toronto Stock Exchange, Bausch + Lomb files annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, along with exhibits such as credit agreements, indentures and press releases.
For an eye health company operating in vision care, surgical products and ophthalmic pharmaceuticals, these filings contain detailed information on segment performance, risk factors, capital structure and governance. Recent Form 8-K filings describe material events including secured notes offerings, amendments to the company’s credit and guaranty agreement, creation of new term loan tranches and revolving credit facilities, refinancing of existing borrowings, quarterly financial results, investor day materials and changes in the composition of the board of directors.
Investors can use this page to review Bausch + Lomb’s disclosures on direct financial obligations, covenants, leverage ratios and maturity profiles, as well as governance items such as director appointments, committee assignments and executive compensation arrangements referenced in current reports. Over time, the archive will also include annual 10-K reports and quarterly 10-Q reports, which provide more comprehensive discussions of the company’s business, segments, risk factors and financial statements.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the nature of new term loans, secured notes, amendments, results of operations and other reported events. Users can also monitor current reports that reference press releases on topics such as investor day presentations, refinancing transactions and quarterly earnings, using this page as a central source for BLCO’s regulatory history and ongoing disclosure record.
Bausch & Lomb Corp executive Robert D. Bailey reported routine share dispositions related to tax withholding on vested equity awards. On two dates, he surrendered 3,395 and 2,461 common shares, respectively, at prices of $18.49 and $18.30 per share to cover tax obligations on restricted share unit vesting, rather than selling shares on the open market. After these tax-withholding transactions, he directly holds 217,290 common shares.
Bausch & Lomb EVP and CFO Sam Eldessouky reported tax-withholding dispositions of common shares related to equity awards. On February 26–27, 2026, he delivered 15,507, 51,470 and 7,062 common shares at prices of $18.30 and $18.49 per share to satisfy tax obligations.
Footnotes explain these shares were withheld upon vesting of restricted share units and performance-based restricted share units, rather than sold in open-market transactions. Eldessouky retains a significant direct holding of Bausch & Lomb common shares after these tax-withholding events.
Bausch & Lomb Corp CEO and Chairman Brent L. Saunders reported two Form 4 transactions reflecting common shares withheld to cover taxes on restricted share units that vested. On February 26, 22,059 common shares at $18.49 per share were withheld. On February 27, an additional 24,649 common shares at $18.30 per share were withheld. These are coded as tax-withholding dispositions rather than open-market sales, and Saunders held 951,875 common shares directly after the most recent transaction.
Munsch Frederick reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corporation Senior Vice President, Controller and Chief Accounting Officer Frederick Munsch received an equity award of 18,253 common shares in the form of restricted share units. The grant was made at no cash cost to him as part of the company’s 2022 Omnibus Incentive Plan.
The RSUs are scheduled to vest in three equal installments on each of the first three anniversaries of the grant date, subject to his continued service and the plan and award agreement terms. After this award, he beneficially owns 108,484 common shares directly.
Bausch & Lomb Corp reported that President, Surgical, Luc Bonnefoy acquired 30,373 common shares through a grant of restricted share units (RSUs) at no cost per share. These RSUs vest one-third on each of the first three anniversaries of the grant date. After this award, Bonnefoy holds 117,937 common shares directly.
Bausch & Lomb Corp reported that executive Andrew J. Stewart, President, GPIC, acquired 32,710 common shares on February 25, 2026 through a grant of restricted share units (RSUs) at $0.00 per share. After this award, he holds 95,640 common shares directly.
The RSUs vest in three equal installments on each of the first three anniversaries of the grant date, generally contingent on his continued service. Once vested, these RSUs will be settled in Bausch & Lomb common shares.
Hashad Yehia reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corp executive Yehia Hashad, EVP of R&D and CMO, received a grant of 35,046 restricted share units (RSUs) on common shares at a price of $0.00 per share. After this equity award, his directly held common shares total 198,906.
The RSUs were granted under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan and are scheduled to vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to continued service and plan terms. Vested RSUs will be settled in common shares of Bausch & Lomb.
Bausch & Lomb Corp reported that EVP & Chief Legal Officer A. Robert D. Bailey acquired an equity award of 52,570 restricted share units (RSUs) on common shares at a stated price of $0.00 per share. These RSUs were granted under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan.
The RSUs are scheduled to vest one-third on each of the first three anniversaries of the grant date, generally requiring Mr. Bailey’s continued service. After this award, his direct holdings in common shares total 223,146 shares, highlighting ongoing stock-based compensation tied to long-term service.
Bausch & Lomb Corp reported that EVP and CFO Sam Eldessouky acquired 81,775 common shares through a grant of restricted share units (RSUs) at a price of $0.00 per share. After this award, he directly holds 473,169 common shares.
The RSUs were granted under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan. They are scheduled to vest in three equal installments on each of the first three anniversaries of the grant date, generally requiring his continued service. Once vested, the RSUs will be settled in common shares of Bausch & Lomb Corporation.
SAUNDERS BRENT L reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corp CEO and chairman Brent L. Saunders received an equity grant of 327,102 restricted share units under the company’s 2022 Omnibus Incentive Plan. These RSUs vest in three equal annual installments and settle in common shares upon vesting. After this award, he holds 998,583 common shares directly.